

Effect of Periodontal Treatment on Glycemic Control of Diabetic Patients

A systematic review and meta-analysis

WIJNAND J. TEEUW, DDS¹
 VICTOR E.A. GERDES, PHD^{2,3}
 BRUNO G. LOOS, PHD¹

OBJECTIVE — There is growing evidence that periodontitis may affect general health. This study was assigned to explore the robustness of observations that periodontal therapy leads to the improvement of glycemic control in diabetic patients.

RESEARCH DESIGN AND METHODS — A literature search (until March 2009) was carried out using two databases (MEDLINE and the Cochrane Library) with language restriction to English. Selection of publications was based on 1) original investigations, 2) controlled periodontal intervention studies where the diabetic control group received no periodontal treatment, and 3) study duration of ≥ 3 months.

RESULTS — Screening of the initial 639 identified studies and reference checking resulted in five suitable articles. A total of 371 patients were included in this analysis with periodontitis as predictor and the actual absolute change in A1C (Δ A1C) as the outcome. The duration of follow-up was 3–9 months. All studies described a research population of type 2 diabetic patients in whom glycemic control improved after periodontal therapy compared with the control group (range Δ A1C: $\Delta -1.17$ up to $\Delta -0.05\%$). The studies in a meta-analysis demonstrated a weighted mean difference of Δ A1C before and after therapy of -0.40% (95% CI -0.77 to -0.04% , $P = 0.03$) favoring periodontal intervention in type 2 diabetic patients. Nevertheless, this improvement in %A1C must be interpreted with care due to limited robustness as evidenced by heterogeneity among studies (59.5%, $P = 0.04$).

CONCLUSIONS — The present meta-analysis suggests that periodontal treatment leads to an improvement of glycemic control in type 2 diabetic patients for at least 3 months.

Diabetes Care 33:421–427, 2010

Periodontitis is a chronic multifactorial infectious disease of the supporting tissues of the teeth (1). It is estimated that between 10 and 15% of adults from 21 to 50 years of age and about 30% of subjects >50 years of age have severe periodontitis (2,3). Clinically, patients suffer from gradual loss of tooth attachment in the alveolar bone leading to periodontal pockets, receding gums, loose teeth, and eventually tooth exfoliation, which may result in changes in diversity of food uptake, possibly affecting

general health (4). Often gums are red and swollen, bleed easily, and patients with periodontitis suffer from bad breath.

Treatment of periodontitis includes mechanical removal of supra- and subgingival bacterial plaque with scalers, cures or ultrasonic devices (scaling and root planing [SRP]), and intensive oral hygiene instructions for the patient. A close to ideal oral hygiene regimen is the only way to prevent formation of new dental plaque deposits and re-infection of the subgingival tissues. The routine use of

systemic or local antibiotics as an adjunctive therapy to SRP is still controversial in terms of improvement of clinical periodontal status (5–7). Surgery regularly is needed to reduce or eliminate deep residual periodontal lesions.

Diabetes and periodontal disease are two chronic diseases that have long been considered to be biologically linked. A large amount of case reports, cross-sectional studies, longitudinal studies, and reviews report the adverse effects of diabetes on the onset, progression, and severity of periodontitis (8,9). The prevalence of periodontitis in diabetic subjects is estimated to be double or even triple the number in the normal population (10). It has been suggested that hyperglycemia and resultant advanced glycation end product formation, which is one of the several pathways that is thought to lead to the classic microvascular and macrovascular complications of diabetes, are also involved in the pathophysiology of periodontitis in diabetic subjects (8).

There is a growing body of evidence supporting the fact that the periodontal infection with gram-negative microorganisms (11,12) adversely affects glycemic control (9,13). Thus, it is now acknowledged that due to untreated or inadequately controlled moderate-to-severe periodontitis, the systemic inflammatory burden may be increased. For example, in periodontitis patients without other apparent diseases, C-reactive protein (CRP) levels are higher compared to subjects without periodontitis (14). Similarly, it has been suggested that a microbiological imbalance in the gut may increase the gram-negative bacterial load, which, through lipopolysaccharides leakage into the circulation, also increases the systematic inflammatory burden. The increased inflammation eventually triggers insulin resistance (15,16).

More direct evidence regarding the effects of periodontal disease on glycemic control of diabetic patients comes from intervention studies using periodontal therapy. Since the beginning of the 1990s, several studies have investigated the association between periodontal therapy and

From the ¹Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University, Amsterdam, the Netherlands; the ²Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; and the ³Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands.

Corresponding author: Wijnand J. Teeuw, w.teeuw@acta.nl.

Received 28 July 2009 and accepted 20 October 2009.

DOI: 10.2337/dc09-1378

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

the improvement of glycemic control in diabetic patients. For example, Iwamoto et al. (17) showed that periodontal treatment in type 2 diabetic patients is effective in improving metabolic control. However, the latter and many other studies are uncontrolled, provide conflicting data, and report short-term results (<3 months). Because of the chronic nature of the development, progression, and severity of complications in diabetic patients, only longer-term results of periodontal treatment are meaningful. Therefore, we put the hypothesis forward that if periodontitis is causally related to the worsening of parameters of diabetic patients, then periodontal treatment should improve glycemic control.

Our aim was to perform a systematic review of intervention studies to answer the question of whether periodontal treatment affects the general health of diabetic patients by improving glycemic control compared with no periodontal treatment after at least 3-month follow-up.

RESEARCH DESIGN AND METHODS

Search strategy

Two databases, MEDLINE (via PubMed) and the entire Cochrane Library, have been searched using free-text search terms and the boolean operators “OR” and “AND”: [“Periodontal disease” OR periodontitis OR “periodontal infection” OR periodont*] AND [“diabetes” OR diabet* OR diabetic* OR “diabetic patient*” OR “diabetes patient*” OR “non insulin dependent diabetes” OR niddm OR “insulin dependent diabetes” OR iddm OR “type 1 diabetes” OR t1dm OR “type 2 diabetes” OR t2dm] AND [therapy OR treatment OR intervention] from January 1960 to 31 March 2009. Additional searches were conducted in MEDLINE’s and Cochrane’s medical subject headings with: [Periodontal diseases] AND [Diabetes Mellitus] AND [Therapeutics OR Therapy OR Intervention studies].

In addition, the reference lists of articles, which were obtained by the electronic search, were searched manually for relevant articles. The language of the studies in the literature search was restricted to English.

Study selection criteria

To be included in the systematic review, studies had to meet the following criteria: 1) original investigations; 2) intervention studies containing diabetic patients with

periodontitis receiving periodontal treatment and diabetic patients with periodontitis receiving no periodontal treatment (controlled clinical trial [CCT] or randomized clinical trial [RCT] design) and outcomes related to metabolic control; 3) studies with a study duration of ≥ 3 months; and 4) studies conducted within a human population.

With the help of these inclusion criteria, the title and abstract of all the articles in the electronic search were evaluated on relevance. From the selected articles, the full texts were reviewed, followed by a decision on their eligibility for inclusion.

Methodological study quality assessment

For RCTs and CCTs, the following parameters were investigated (standard assessment form developed by the Dutch Cochrane Centre and the Dutch Institute for Healthcare Improvement CBO (<http://www.cochrane.nl/nl/newPage1.html>): 1) allocation concealment, 2) randomization, 3) blindness of examiner and/or patient, and 4) loss to follow-up.

Data extraction and statistical analysis

From all relevant studies, the main features that were extracted were 1) characteristics of the population (i.e., age, sex, country of birth, extent), 2) definition of diabetes (i.e., type, duration, metabolic control), 3) definition of periodontitis, and 4) intervention (i.e., type, duration), study duration, outcome, and study design.

All suitable data for a meta-analysis were entered and analyzed with RevMan 4.2 (<http://www.cc-ims.net/RevMan>). A meta-analysis was conducted for RCTs and CCTs in which the intervention group received SRP (with or without adjunctive antimicrobial therapy), and the control group received no periodontal therapy. The absolute difference (Δ) in %A1C for baseline-end, if not reported in the article, was calculated for the intervention and the control groups by means of the formula:

$$\Delta \%A1C_{ti} = \%A1C_{ti1} - \%A1C_{ti2},$$

where %A1C_{ti1} is the mean %A1C value before treatment and %A1C_{ti2} is the mean %A1C after treatment. Again, if not reported, for some studies, the variance (and consequently SD) of Δ %A1C_{ti} was estimated as follows (18):

$$S_{ti}^2 = S_{ti1}^2 + S_{ti2}^2 - 2r \cdot S_{ti1} \cdot S_{ti2},$$

where S_{ti}^2 is the variance of Δ in %A1C levels, S_{ti1}^2 is the variance of the mean baseline %A1C values, S_{ti2}^2 is the variance of the mean end %A1C value, r is the correlation between the baseline and end values, and S_{ti1} and S_{ti2} are the SDs of the baseline and end values, respectively. We assumed r to be 0.5 as was previously described (19).

For each meta-analysis, the weighted mean difference (WMD) was calculated, nested in a random-effects model with corresponding Z statistics, P values, and 95% CIs. Also, a test for heterogeneity was performed. For this test, the I^2 statistic describes the proportion of total variation due to heterogeneity where 0% indicates no heterogeneity and 100% indicates maximal heterogeneity among the studies included in the meta-analysis (20). Heterogeneity indicates the robustness of the WMD. The results of the meta-analysis are presented in a forest plot with the following indicators 1) the raw data (means and SDs) for each arm per included study; 2) point estimates and CIs for the chosen effect measure, as blocks and lines, respectively; 3) heterogeneity statistic (I^2); 4) the total number of participants per group; 5) the overall average effect (WMD and Z statistics) in a random-effects model; and 6) percent weight given to each study.

RESULTS— The combined MEDLINE (via PubMed) and the Cochrane Central searches resulted in 639 potentially eligible articles (Fig. 1). These articles were screened by title and abstract for relevance. The screening resulted in 74 articles that qualified for full-text reading. After full-text reading, 40 articles were deemed unsuitable and were therefore excluded (supplemental Table 1A and C, which is available in an online appendix at <http://care.diabetesjournals.org/cgi/content/full/dc09-1378/DC1>). Screening of the reviews ($n = 29$) (supplemental Table 1B) for unpublished data did not provide any additional articles. Supplemental Table 1C presents the excluded intervention studies ($n = 35$) and the main reason for exclusion. Five articles (three RCTs and two CCTs) fulfilled the inclusion criteria and were processed for data extraction (Table 1) (21–25).

General characteristics

From the five included studies, two were performed in North America (the U.S.) (21,25), two were performed in Asia




Figure 1—Flow chart outlining the search strategy and results along various steps.

(Japan [22] and Thailand [24]), and one was performed in the Middle East (Turkey) (23). The study duration ranged from 3 to 9 months. All studies described a study population having type 2 diabetes and suffering from periodontitis. In total, 199 patients (range 22–82 patients per study) were in the intervention group and 183 patients (range 17–83 patients per study) were in the control group. The mean age per study ranged from 56 to 62 years for the intervention group and from 53 to 67 years for the control group. In addition, the baseline A1C levels per study ranged from 7.2 to 9.9% for the intervention group, whereas the baseline A1C levels for the control group ranged from 6.9 to 10.2%.

All subjects in the intervention group received SRP with (21,22,24) or without (23,25) local or systemic administration of antibiotics, whereas no subject of the

control group received any form of periodontal intervention.

Periodontal intervention and A1C

All studies reported absolute changes (Δ) in A1C as parameter of metabolic control. Four of the five studies reported mean differences between baseline and end of trial with or without SDs (21,23–25). One study (22) reported changes of A1C levels graphically; the mean values and SDs were obtained through e-mail communication with the authors. Two of the five studies showed a significant improvement in metabolic control after periodontal treatment as measured by a significant decrease in A1C levels compared with that in the untreated control group ($I_{\text{intervention}} - C_{\text{control}}$ [I-C] $\Delta -1.17\%$ [(23)], $I - C \Delta -1.10\%$ [(25)]). Katagiri et al. (22), Jones et al. (21), and Promsudthi et al.

(24) also showed a decrease in A1C levels after periodontal therapy (I-C $\Delta -0.05\%$, I-C $\Delta -0.16\%$, and I-C $\Delta -0.31\%$, respectively); however, these decreases were reported to be not significant. A multiple regression analysis in the study by Katagiri et al. (22) for significant variables associated with changes of A1C levels between baseline and 6 months showed that the A1C decrease correlated with decreases in high-sensitivity CRP (hs-CRP) levels after periodontal treatment ($P = 0.03$) (22). Based on this analysis, Katagiri et al. (22) divided the intervention group into CRP-decreased and CRP-unchanged groups. This subanalysis showed that A1C levels decreased significantly in the CRP-decreased group compared with baseline levels, but not in the CRP-unchanged group.

Periodontal intervention and other parameters of glycemic control

Three studies also reported change in fasting plasma glucose (FPG) as parameter of metabolic control, and two studies showed a nonsignificant decrease in FPG after periodontal treatment compared with that in the control group (I-C $\Delta -5.18$ mg/dl [23], I-C $\Delta -3.83$ mg/dl [24]). Notably, Katagiri et al. (22) showed a nonsignificant deterioration of metabolic control as reflected by a nonsignificant increase in FPG after periodontal treatment compared with that in the control group (I-C $\Delta 22$ mg/dl). In addition, Kiran et al. (23) showed a significant decrease of 2-h postprandial glucose (PPG) levels after periodontal therapy compared with baseline levels of the treatment group ($I_{\text{end of trial}} - I_{\text{baseline}} \Delta -23.6$ mg/dl, $P = 0.027$). However, compared with that in the control group, the decrease in 2-h PPG levels was not significant (I-C $\Delta -25.1$ mg/dl, $P = 0.067$).

Meta-analysis

The effect of periodontal treatment on A1C levels (five studies) and FPG levels (three studies) could be analyzed from the available intervention studies (Fig. 2A and B). The range of A1C mean differences between baseline and end for the treatment groups was -1.90 to -0.14% , whereas the untreated individuals showed a range of -0.80 to 0.31% . The WMD of A1C mean differences baseline to end between treatment groups and control groups was -0.40% (95% CI -0.04 to -0.77%) (test of the overall effect, $P = 0.03$). The heterogeneity (I^2) be-

Table 1—Included treatment studies reporting study characteristics, definition of periodontal disease, definition of diabetes, results, and quality assessment in reverse chronological order

Author(s)	Population	Definition of periodontal disease (inclusion criteria)	Definition of diabetes (inclusion criteria; baseline A1C levels; diabetes duration)	Intervention	Study duration (observation points)	Outcome	Design	Number of included patients (men)	Results	Quality*
Katagiri et al. 2009 (22)	Diabetic patients with periodontitis (mean age I: 60.3 ± 9.9 years; C: 59.0 ± 4.8 years) at five diabetic clinics in four cities: Tokyo, Kagoshima, Aichi, and Kyoto (Japan)	-Total ≥11 teeth -≥ 2 sites with PPD ≥4 mm	-Inclusion criteria: Type 2 diabetes with A1C value between 6.5 and 10.0% -Baseline % A1C: I: 7.2 ± 0.9 C: 6.9 ± 0.9 -Duration (years) I: 11.3 ± 6.4 C: 8.8 ± 7.5	I: SRP + topical administration of 10 mg minocycline ointment in every periodontal pocket C: Oral hygiene instructions	6 months (1, 3, and 6 months)	-A1C -FPG -hs-CRP -Multiple regression model for changes of A1C levels between baseline and 6 months	RCT	I: 32 (NR) C: 17 (NR)	-% A1C: I: Δ-0.14 (P-be < 0.05) C: Δ+0.09 (P > 0.05) -FPG (mg/dl): I: Δ19 C: Δ-3 (P > 0.05) -hs-CRP: I and C: No significant change was observed during the whole study. -Multiple regression model A1C changes: Baseline BMI: 0.33 (P = 0.03) Changes in hs-CRP: 0.33 (P = 0.03)	+
Jones et al. 2007 (21)	Diabetic patients with periodontitis (mean age I: 59 years; C: 60 years) at four VA facilities, Boston, MA	-Total ≥8 teeth -CPTN score ≥3 in ≥2 sextants	-Inclusion criteria: Type 2 diabetes with ≥1 A1C value of ≥8.5% in the last 6 months and a baseline A1C value of ≥8.5% -Baseline % A1C: I: 9.9 C: 10.2 -Duration (years): I: 11.4 C: 14.1	I: SRP + doxycycline (100 mg/day for 14 days) + CHX rinses (0.12%, twice daily for 4 months) C: Regular dental care	4 months (0 and 4 months)	-A1C	RCT	I: 82 (82) C: 83 (78)	-% A1C: I: Δ-0.65 C: Δ+0.49 (P > 0.05)	+
Kiran et al. 2005 (23)	Diabetic patients with periodontitis (mean age I: 55.95 ± 11.21 years; C: 52.82 ± 12.27 years) from the Faculty of Medicine, Department of Metabolic Diseases & Endocrinology, Ankara University, Turkey	NR	-Inclusion criteria: Type 2 diabetes with A1C value between 6 and 8% -Baseline % A1C: I: 7.31 ± 0.74 C: 7.00 ± 0.72 -Duration (years): I: 9.32 ± 8.36 C: 8.05 ± 5.90	I: SRP C: No treatment	3 months (0 and 3 months)	-A1C -FPG -2-h PPG	RCT	I: 22 (10) C: 22 (8)	-% A1C: I: Δ-0.86 (P-be = 0.0000) C: Δ0.31 (P = 0.033) -FPG (mg/dl): I: Δ-3.96 C: Δ1.22 (P = 0.481) -2-h PPG (mg/dl): I: Δ-23.6 (P-be = 0.027) C: Δ1.5 (P = 0.067)	+
Promsudhi et al. 2005 (24)	Diabetic patients with periodontitis (mean age I: 61.11 ± 5.83 years; C: 61.64 ± 5.81 years) at the Diabetic Clinic of Rajavithi Hospital, Bangkok, Thailand	Total ≥14 teeth with ≥8 sites with PPD ≥5 mm and CAL ≥5 mm	-Inclusion criteria: Type 2 diabetes with A1C values between 7.5 and 11.0% -Baseline % A1C: I: 8.98 ± 0.88 C: 9.17 ± 1.02 -Duration (years): I: 8.30 ± 4.21 C: 14.36 ± 7.57	I: SRP + doxycycline (100 mg/day for 14 days) C: No treatment	3 months (0 and 3 months)	-A1C -FPG	CCT	I: 27 (11) C: 25 (8)	-% A1C: I: Δ-0.19 C: Δ0.12 (P > 0.05) -FPG (mg/dl): I: Δ-3.63 C: Δ0.2 (P > 0.05)	+/-

Table 1—Continued

Author(s)	Population	Definition of periodontal disease (inclusion criteria)	Definition of diabetes (inclusion criteria; baseline A1C levels; diabetes duration)	Intervention	Study duration (observation points)	Outcome	Design	Number of included patients (men)	Results	Quality*
Stewart et al. 2001 (25)	Diabetic patients with periodontitis (mean age I: 62.4 ± 8.4 years; C: 67.3 ± 10.8 years [P = 0.05]) at the VA Los Angeles Outpatient Diabetic Clinic, Los Angeles, CA	NR	-Inclusion criteria: Type 2 diabetes -Baseline % A1C: I: 9.5 ± 2.2 C: 8.5 ± 2.1	I: SRP + extraction of teeth with periapical radiolucencies and sufficient periodontal destruction C: No treatment. Nothing was known regarding the dental status of the control group.	18 months (0 and 9 months)	-A1C	CCT	I: 36 (NR) C: 36 (NR)	-% A1C: I: Δ -1.9 (P-be = 0.0001) C: Δ 0.8 (P = 0.02)	+/-

* +, good quality; +/-, doubtful quality; C, control group; CAL, clinical attachment level; CPITN score, Community Periodontal Index of Treatment Need score; I, intervention group; NR, not reported; P-be, P value for the difference between baseline and end of trial; PPD, probing pocket depth; VA, U.S. Department of Veterans Affairs; Δ , difference between baseline and end of trial.

tween the five studies was 59.5% ($P = 0.04$) (Fig. 2A).

The range of FPG mean differences between baseline and end for the treatment groups was -3.63 to 19.00 mg/dl, whereas the untreated individuals showed a range of -3.00 to 1.22 mg/dl. The WMD of mean FPG differences baseline-end between treatment groups and control groups was 2.30 mg/dl (95% CI -13.64 to 18.24 mg/dl) (test of the overall effect, $P = 0.78$). The heterogeneity (I^2) between the three studies was 23.7% ($P = 0.27$) (Fig. 2B).

CONCLUSIONS— The current review provides the most accurate reflection of available literature to date to answer the question of whether periodontal treatment affects the general health of type 2 diabetic patients by improving glycemic control compared to no periodontal treatment after at least 3-month follow-up. Although previous systematic reviews on this topic (5,26) were conducted, we believe that the current inclusion criteria of available studies result in a better understanding of the effect of periodontal treatment on diabetic patients for the following reasons: 1) We included only studies with at least 3-month follow-up. A1C is a reflection of the mean blood glucose concentration over the preceding 1–3 months and a difference over a shorter period may be clinically less relevant (13). 2) We only used controlled studies in our analysis in which the control group with type 2 diabetes received no periodontal treatment to overcome the problem of a possible Hawthorne effect (27). 3) The calculation of WMD is the most suitable parameter for a proper meta-analysis (28) since back-transformation of a standardized mean difference (5) will lead to an overestimation of the total effect of periodontal therapy.

Thus, we conclude from the current systematic review, based on strict inclusion criteria of literature, that periodontal therapy for type 2 diabetic patients with periodontitis is favorable and can reduce A1C levels on average by 0.40% more than in nonintervention control subjects.

Changes in (blood) levels of markers, which reflect the metabolic regulation of diabetes

Although only two of the five studies showed an improvement of metabolic control after periodontal treatment (23,25), the results of all studies combined in our meta-analysis suggest that

periodontal treatment results in an absolute decrease of A1C of 0.40% compared with no periodontal treatment in type 2 diabetic patients. This decrease of A1C is also clinically relevant since any decrease of A1C will result in less diabetic complications (29,30).

Interestingly, the improvement in glucose metabolism, as evidenced by the reduction of %A1C, was not seen in FPG levels (Fig. 2B). However, FPG levels reflect the metabolic control at one time point and one moment of the day, whereas A1C reflects glucose metabolism over the preceding 1–3 months; this is also true for PPG levels.

The results of our A1C meta-analysis need to be viewed with caution for four main reasons: 1) The lack of robustness as revealed by the significant heterogeneity. Inadequate attention to heterogeneity may result in misinterpretation of the results (31). For example, there is only minor overlap of the CIs between the Kiran et al. (23) and Katagiri et al. (22) trials, suggesting that these studies are less comparable; differences in ethnicity and lifestyle factors may be a possible explanation. 2) The small number of studies ($n = 5$) with relative small study groups. There is a lack of large randomized controlled intervention trials in type 2 diabetic patients. 3) The shortcomings in study design of several studies. Two studies used groups with selection bias by placing treatment avoiders in the control group (24,25). Two other studies used metabolically controlled diabetic patients as determined by a %A1C of ≤ 7 , possibly affecting improvement of metabolic control after periodontal treatment (22,23). Furthermore, the use of systemic or local antibiotics as an adjunctive therapy to basic periodontal treatment is possibly another factor of study design that may influence the outcome. It is interesting to note that the only two studies in our meta-analysis that showed a significant decrease in A1C levels after periodontal treatment did not use antibiotics as an adjunctive therapy (23,25), whereas the other studies did use antibiotics. The use of antibiotics is still controversial whether it is beneficial in terms of improvement of clinical periodontal status (5–7) or glycemic control (32,33). It is clear that further trials specifically addressing this adjunctive form of periodontal therapy are needed. 4) The lack of an instrument to quantify periodontal inflammation for all studies. Inflammation is associated with the onset and progression of diabetes




Figure 2—Forest plots presenting WMD of Δ baseline–end %A1C levels (A) and Δ baseline–end FPG levels in mg/dl (B) between the treatment groups and control groups, heterogeneity and overall effect for treatment studies. diff, difference; B, baseline; E, end; Ctrl, control group; Tx, treatment group.

(15,16). Quantifying the amount of periodontal inflammation and possibly also quantifying the pathogenic bacterial load, together with the improvement of metabolic control, will give us more insight into the relation between periodontitis and diabetes. Most likely, treatment of the generalized severe form of periodontitis will be more beneficial in terms of glyce-mic control of diabetic patients than treat-ment of the localized moderate form of periodontitis. Recently, a new tool has been developed to quantify the inflamma-tory burden of periodontitis (34) and showed that the amount of periodontal inflammation was related to A1C values of diabetic patients in a dose-responded way (35). Regarding the relation between sys-temic inflammatory burden and diabetes, one study (22) reported the effect of peri-odontal treatment on hs-CRP blood levels in diabetic patients. The authors revealed in a multiple regression analysis of all sub-jects that Δ hs-CRP levels at 1 month after periodontal treatment correlated signifi-cantly with the reduction of A1C at 6 months after periodontal treatment. It suggests that change in hs-CRP level is a factor related to the change in A1C level. It has been reported that inflammation di-rectly induces insulin resistance in type 2 diabetic patients (36). Some other studies reported significant decrease of plasma levels of several inflammation markers (reactive oxygen species, interleukin [IL]-1 β , IL-6) compared with baseline levels after periodontal therapy (37,38). Some

of these inflammatory cytokines (tumor necrosis factor [TNF]- α , IL-6, and IL-1) have been shown to have important ef-fects on glucose and lipid metabolism by antagonizing the insulin action (IL-6 and IL-1) and/or interfering with lipid metab-olism (TNF- α) (9,15,36,39). For exam-ple, Iwamoto et al. (17) already suggested that periodontal treatment in type 2 dia-betic patients is effective in improving metabolic control possibly through re-duced TNF- α levels and improved insulin resistance. However, this study did not use an untreated control group and there-fore was not included in the current sys-tematic review.

We have shown that periodontal treatment leads to improvement of the general health of type 2 diabetic patients by affecting the metabolic control: after periodontal treatment, A1C can be signifi-cantly reduced by absolute 0.40% based on RCTs and CCTs with at least 3-month follow-up. However, more evidence is needed as is reflected by a wide CI. More homogeneous evidence is needed as is re-lected by a significant heterogeneity (0.59%) among the studies. We propose further trials to be initiated as follows (40):

- A large single-blind randomized con-trolled study of diabetic patients with moderate or severe periodontitis.
- The treatment group to receive basic periodontal treatment (oral hygiene instruction and SRP), whereas the

control group not to receive any form of periodontal treatment.

- Follow-up period ≥ 6 months.
- Sample size is large enough to analyze patients with moderate and severe pe-riodontitis separately.
- Outcome:
 - Change in (plasma) markers of glyce-mic control.
 - Change in the amount of periodontal inflammation.
 - Change in (plasma) markers of sys-temic inflammation.

ADDENDUM— No new studies ac-cording to the inclusion criteria of this article have appeared in the literature as of the time of the production of this article (November 2009).

Acknowledgments— This work was sup-ported by the College of Health Insurances (CvZ), Amsterdam, the Netherlands, which supplied a grant for literature reviews related to the effects of periodontal therapy in patients with chronic medical conditions.

No potential conflicts of interest relevant to this article were reported.

References

1. Persson GR. What has ageing to do with periodontal health and disease? *Int Dent J* 2006;56:240–249
2. Brown LJ, Oliver RC, Loe H. Evaluating periodontal status of US employed adults. *J Am Dent Assoc* 1990;121:226–232
3. Gjermo P. Epidemiology of periodontal

- diseases in Europe. *J Periodontol Implan-*
tol 1998;111–121
4. Hung HC, Willett W, Ascherio A, Rosner BA, Rimm E, Joshipura KJ. Tooth loss and dietary intake. *J Am Dent Assoc* 2003; 134:1185–1192
 5. Darré L, Vergnes JN, Gourdy P, Sixou M. Efficacy of periodontal treatment on glycaemic control in diabetic patients: a meta-analysis of interventional studies. *Diabetes Metab* 2008;34:497–506
 6. Llambés F, Silvestre FJ, Hernández-Mijares A, Guiha R, Caffesse R. Effect of non-surgical periodontal treatment with or without doxycycline on the periodontium of type 1 diabetic patients. *J Clin Periodontol* 2005;32:915–920
 7. Martorelli de Lima AF, Cury CC, Palioto DB, Duro AM, da Silva RC, Wolff LF. Therapy with adjunctive doxycycline local delivery in patients with type 1 diabetes mellitus and periodontitis. *J Clin Periodontol* 2004;31:648–653
 8. Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. *Curr Opin Endocrinol Diabetes Obes* 2008;15: 135–141
 9. Taylor GW, Borgnakke WS. Periodontal disease: associations with diabetes, glycaemic control and complications. *Oral Dis* 2008;14:191–203
 10. Mealey BL, Oates TW, the American Academy of Periodontology. Diabetes mellitus and periodontal diseases. *J Periodontol* 2006;77:1289–1303
 11. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. *J Clin Periodontol* 1998;25:134–144
 12. van Winkelhoff AJ, Loos BG, van der Reijden WA, van der Velden U. *Porphyromonas gingivalis*, *Bacteroides forsythus* and other putative periodontal pathogens in subjects with and without periodontal destruction. *J Clin Periodontol* 2002;29: 1023–1028
 13. Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. *Periodontol* 2000 2007;44:127–153
 14. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. *J Clin Periodontol* 2008;35:277–290
 15. King GL. The role of inflammatory cytokines in diabetes and its complications. *J Periodontol* 2008;79:1527–1534
 16. Serino M, Luche E, Chabo C, Amar J, Burcelin R. Intestinal microflora and metabolic diseases. *Diabetes Metab* 2009;35: 262–272
 17. Iwamoto Y, Nishimura F, Nakagawa M, Sugimoto H, Shikata K, Makino H, Fukuda T, Tsuji T, Iwamoto M, Murayama Y. The effect of antimicrobial periodontal treatment on circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. *J Periodontol* 2001;72:774–778
 18. Rosner B. *Fundamentals of Biostatistics*. 5th ed. Pacific Grove, CA, Duxbury Press, 2000, p. 135–138
 19. Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A. Elevated serum interleukin-6 (IL-6) in solid-organ transplant recipients is positively associated with tissue destruction and IL-6 gene expression in the periodontium. *J Periodontol* 2006;77:1871–1878
 20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–1558
 21. Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, Christiansen CL, Rothendler JA, Garcia RI. Does periodontal care improve glycaemic control? The Department of Veterans Affairs Dental Diabetes Study. *J Clin Periodontol* 2007;34:46–52
 22. Katagiri S, Nitta H, Nagasawa T, Uchimura I, Izumiyama H, Inagaki K, Kikuchi T, Noguchi T, Kanazawa M, Matsuo A, Chiba H, Nakamura N, Kanamura N, Inoue S, Ishikawa I, Izumi Y. Multi-center intervention study on glycohemoglobin (HbA1c) and serum, high-sensitivity CRP (hs-CRP) after local anti-infectious periodontal treatment in type 2 diabetic patients with periodontal disease. *Diabetes Res Clin Pract* 2009;83:308–315
 23. Kiran M, Arpak N, Unsal E, Erdoğan MF. The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus. *J Clin Periodontol* 2005;32: 266–272
 24. Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanasavita W. The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. *Oral Dis* 2005;11:293–298
 25. Stewart JE, Wager KA, Friedlander AH, Zadeh HH. The effect of periodontal treatment on glycaemic control in patients with type 2 diabetes mellitus. *J Clin Periodontol* 2001;28:306–310
 26. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment improve glycaemic control in diabetic patients? A meta-analysis of interventional studies. *J Dent Res* 2005;84: 1154–1159
 27. Watts T. Periodontal treatment and glycaemic control in diabetic patients: the problem of a possible Hawthorne effect. *J Dent Res* 85:294
 28. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In *Systematic Reviews in Health Care: Meta-Analysis in Context*. Egger M, Smith GD, Altman DG, Eds. London, BMJ Publishing Group, 2007, p. 290
 29. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F. Implications of the United Kingdom Prospective Diabetes Study: American Diabetes Association (Position Statement). *Diabetes Care* 2003;26(Suppl. 1):S28–S32
 30. Unger J. Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus. *Am J Med* 2008;121:S3–S8
 31. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. *Clin Med* 2001; 1:478–484
 32. Grossi SG, Skrepinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. *J Periodontol* 1997;68:713–719
 33. Rodrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF. Effect of non-surgical periodontal therapy on glycaemic control in patients with type 2 diabetes mellitus. *J Periodontol* 2003;74:1361–1367
 34. Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. Periodontal inflamed surface area: quantifying inflammatory burden. *J Clin Periodontol* 2008;35:668–673
 35. Nesse W, Linde A, Abbas F, Spijkervet FK, Dijkstra PU, de Brabander EC, Gerstenbluth I, Vissink A. Dose-response relationship between periodontal inflamed surface area and HbA1c in type 2 diabetics. *J Clin Periodontol* 2009;36: 295–300
 36. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. *Diabet Med* 2004; 21:810–817
 37. Al-Mubarak S, Ciancio S, Aljada A, Mohanty P, Ross C, Dandona P. Comparative evaluation of adjunctive oral irrigation in diabetics. *J Clin Periodontol* 2002;29: 295–300
 38. O'Connell PA, Taba M, Nomizo A, Foss Freitas MC, Suaid FA, Uyemura SA, Trevisan GL, Novaes AB, Souza SL, Palioto DB, Grisi MF. Effects of periodontal therapy on glycaemic control and inflammatory markers. *J Periodontol* 2008;79: 774–783
 39. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia* 1997;40:1286–1292
 40. Garcia R. Periodontal treatment could improve glycaemic control in diabetic patients. *Evid Based Dent* 2009;10:20–21